移植相关血栓性微血管病中的干扰素-补体环路
该研究对造血干细胞移植后发生与未发生TA-TMA的儿童,在移植前、TA-TMA发病时及缓解后采集外周血单个核细胞进行转录组分析,发现活动性TA-TMA时经典、替代和凝集素补体途径均显著上调,且伴随干扰素特征和STAT1/STAT2信号增强,补体阻断后均恢复 baseline。
要点
- 活动性TA-TMA时多条补体途径上调,补体阻断缓解后基因表达恢复基线。
- TA-TMA存在干扰素特征及STAT1/STAT2信号增强,补体阻断后消退。
- 提出「干扰素-补体环路」模型解释内皮损伤持续和血栓性微血管病。
核心结论
- TA-TMA活动期存在多条补体途径激活及干扰素信号增强,补体阻断缓解后均恢复。
- 提出干扰素-补体环路模型,可持续内皮损伤和血栓性微血管病。
研究设计与样本
- 对移植后发生与未发生TA-TMA的儿童,在HSCT前、TA-TMA发病时及缓解后采集外周血单个核细胞行转录组分析。
主要发现
- 活动性TA-TMA时经典、替代和凝集素补体途径显著上调。
- 上调基因和通路在eculizumab治疗缓解后基本恢复基线表达。
- TA-TMA伴随干扰素特征及STAT1、STAT2信号增强,补体阻断后消退。
关键数值与推荐
- TA-TMA补体激活涉及多条途径,不同于aHUS主要经替代途径激活。
临床怎么用
- 支持TA-TMA缓解后停用补体阻断的临床实践。
- 提示可探索新型补体阻断剂及抗补体联合抗干扰素治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transplant-associated thrombotic microangiopathy (TA-TMA) is an important cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The complement inhibitor eculizumab improves TA-TMA, but not all patients respond to therapy, prompting a search for additional targetable pathways of endothelial injury. TA-TMA is relatively common after HSCT and can serve as a model to study mechanisms of tissue injury in other thrombotic microangiopathies. In this work, we performed transcriptome analyses of peripheral blood mononuclear cells collected before HSCT, at onset of TA-TMA, and after resolution of TA-TMA in children with and without TA-TMA after HSCT. We observed significant upregulation of the classical, alternative, and lectin complement pathways during active TA-TMA. Essentially all upregulated genes and pathways returned to baseline expression levels at resolution of TA-TMA after eculizumab therapy, supporting the clinical practice of discontinuing complement blockade after resolution of TA-TMA. Further analysis of the global transcriptional regulatory network showed a notable interferon signature associated with TA-TMA with increased STAT1 and STAT2 signaling that resolved after complement blockade. In summary, we observed activation of multiple complement pathways in TA-TMA, in contrast to atypical hemolytic uremic syndrome (aHUS), where complement activation occurs largely via the alternative pathway. Our data also suggest a key relationship between increased interferon signaling, complement activation, and TA-TMA. We propose a model of an "interferon-complement loop" that can perpetuate endothelial injury and thrombotic microangiopathy. These findings open opportunities to study novel complement blockers and combined anti-complement and anti-interferon therapies in patients with TA-TMA and other microangiopathies like aHUS and lupus-associated TMAs.
引用
- Jodele S, Medvedovic M, Luebbering N, et al. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020. PMID: 32208488. doi:10.1182/bloodadvances.2020001515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。